Xeljanz (tofacitinib) is a prescription medication used to treat adults with moderate to severe rheumatoid arthritis and psoriatic arthritis. It is the first and only Janus kinase (JAK) inhibitor approved by the US Food and Drug Administration (FDA). Xeljanz works by blocking certain proteins that play a role in inflammation and the progression of RA and PsA.
Xeljanz works by blocking the Janus kinases that are responsible for the inflammation that is associated with rheumatoid arthritis. By blocking these proteins, Xeljanz is able to reduce the inflammation and pain associated with rheumatoid arthritis. Additionally, Xeljanz has been shown to reduce the number of swollen and painful joints in patients with rheumatoid arthritis. The effects of Xeljanz may take several weeks to become apparent. In studies, most patients experienced a decrease in joint pain and swelling within six weeks of starting treatment. For some patients, it may take up to twelve weeks for the full effects of Xeljanz to be seen.
Xeljanz can be a useful treatment option for people with RA and PsA who have not had success with other medications. It can help reduce joint pain and swelling, as well as improve physical function. Xeljanz has been shown to be effective in clinical trials, but it is important to discuss the potential risks and benefits with your doctor before starting treatment. Xeljanz can be an effective treatment option for adults with RA and PsA who have not had success with other medications.
You can buy xeljanz online at softcarepharmacy.com